Gong Jun, Maia Manuel Caitano, Dizman Nazli, Govindarajan Ameish, Pal Sumanta K
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Division of Medical Oncology, Instituto Hemomed de Oncologia e Hematologia. Av. Arnolfo de Azevedo, 121 - Cerqueira César - CEP 01248-040, Sao Paulo, Brazil.
Asian J Urol. 2016 Oct;3(4):286-292. doi: 10.1016/j.ajur.2016.08.006. Epub 2016 Aug 30.
Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis.
尽管肾细胞癌(RCC)的全身治疗已取得多项进展,但转移性RCC仍然无法治愈。在当前的综述中,我们聚焦于RCC的潜在生物学特性及可能的转移机制。我们进一步概述了通过辅助治疗对抗转移的不断发展的策略。最后,我们讨论了RCC的转移临床模式,以及如何根据转移的解剖位置考虑不同的全身治疗方法。